Telehealth platforms prescribe GLP-1 drugs off-label for addiction as FDA approval lags
Source Summary
Telehealth companies are prescribing GLP-1 drugs off-label to treat addiction, bypassing the formal FDA approval process. Medical experts express concern about fragmented care and potential unknown risks to patients from this unapproved use.
Why it matters
Off-label GLP-1 prescribing for addiction through telehealth circumvents regulatory oversight and may expose patients to unproven treatments without the safety data required for formal FDA approval.
What remains uncertain
The extent of off-label GLP-1 prescribing for addiction and the specific health outcomes or adverse events associated with this practice remain unclear.
